The Technical Analyst
4D pharma plc [LBPS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
4D pharma plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $1.650
America/New_York / 31 des 1970 @ 19:00
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/18 | 2/19 | 2/20 | 4/20 | 2/21 | 4/21 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.430 - 1.870 ( +/- 13.33%) |
| ATR Model: 14 days |
Forecast:
01:40 - $2.97
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.650 (0.00% ) |
| Volume | 0.0039 mill |
| Avg. Vol. | 0.0113 mill |
| % of Avg. Vol | 34.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LBPS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LBPS
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
Latest Press Releases
2022-03-23 07:00:00 - Press Release
4d Pharma Announces Positive Interim Results From The Phase I/ii Study Of The Combination Of Mrx0518 And Keytruda® (pembrolizumab) For The Treatment Of Renal Cell Carcinoma
Leeds, england--(business wire)--4d pharma plc (aim: dddd, nasdaq: lbps), a pharmaceutical company leading the development of live biotherapeutic products (lbps), a novel class of drug derived from the microbiome, today announces that in part b of its signal finding study of mrx0518 in combination with msd’s anti-pd-1 therapy, keytruda® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ici), the renal cell carcinoma (rcc) group has met its primary efficacy endpoint ahead of enrollment completion. the ongoing study is being conducted in heavily pre-treated metastatic patients with solid tumors who have previously experienced clinical benefit on prior ici therapy and subsequently developed progressive disease...
2022-01-27 07:00:00 - Press Release
4d Pharma Announces Additional Positive Data From Part A Of The Phase I/ii Trial Of Mrx-4dp0004 For The Treatment Of Asthma
Leeds, england--(business wire)--4d pharma plc (aim: dddd, nasdaq: lbps), a pharmaceutical company leading the development of live biotherapeutic products (lbps), a novel class of drug derived from the microbiome, today announces additional clinical data from part a of its phase i/ii trial of mrx-4dp0004, an orally-delivered single strain live biotherapeutic being developed for the treatment of asthma. the company previously reported topline safety and efficacy data from part a, and today announces additional details of these results. the phase i/ii trial is a multi-center, double-blind, placebo-controlled study in patients with partly controlled asthma taking long-term medication. the primary endpoint of part a was to evaluate the safety and tolerability of mrx-4dp0004...
2021-09-15 07:00:00 - Press Release
4d Pharma Presents Two Clinical Posters For Live Biotherapeutic Mrx0518 At The European Society For Medical Oncology (esmo) Congress 2021
Leeds, england--(business wire)--4d pharma plc (aim: dddd, nasdaq: lbps), a pharmaceutical company leading the development of live biotherapeutic products (lbps), a novel class of drug derived from the microbiome, today announces new biomarker analyses from two ongoing clinical trials of its lead immuno-oncology single strain live biotherapeutic, mrx0518, in both neoadjuvant and refractory solid tumor settings, at the european society for medical oncology (esmo) congress, september 16-21, 2021.
2021-08-02 07:00:00 - Press Release
4d Pharma Announces Two Presentations At European Society For Medical Oncology (esmo) Congress 2021
Leeds, england--(business wire)--4d pharma plc (aim: dddd, nasdaq: lbps), a pharmaceutical company leading the development of live biotherapeutic products (lbps), a novel class of drug derived from the microbiome, today announces two poster presentations at the european society for medical oncology (esmo) congress, held from september 16-21, 2021. the two e-posters will be available from 07:30 bst (02:30 et) on september 16, 2021. poster presentation details are as follows: presentation title: baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (icis) treated with live biotherapeutic mrx0518 in combination with pembrolizumab presenting author: dr...
2021-06-04 07:00:00 - Press Release
4d Pharma Completes Enrollment Of Part A Of The Phase I/ii Trial Of Mrx-4dp0004 For The Treatment Of Asthma And Provides Program Update
Leeds, england--(business wire)--4d pharma plc (aim: dddd, nasdaq: lbps), a pharmaceutical company leading the development of live biotherapeutic products (lbps), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment of 30 patients for part a of its phase i/ii clinical trial of mrx-4dp0004 in patients with partly-controlled asthma. following the completion of enrollment of part a, 4d pharma expects to announce topline results from these patie
Latest News
2022-11-16 02:47:02 - Proactive Investors
4D pharma says phase II IBS results published in scientific journal
4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific publication. The article in Alimentary Pharmacology & Therapeutics took a deeper dive into the already revealed finding that the drug has an impact on the symptoms of the two separate IBS cohorts – those with constipation and those with diarrhoea.
2022-05-27 02:50:45 - Proactive Investors
4D Pharma outlines phase II plans for promising cancer drug candidate
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the plans and aims of a phase II study of its cancer drug candidate used alongside an immune checkpoint inhibitor drug. Delegates at the American Society of Clinical Oncology meeting in Chicago will be told that MRx0518 will be coupled with Bavencio to treat a common form of bladder cancer.
2022-05-17 02:29:20 - Proactive Investors
4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will present an update from the phase I/II trial of its putative asthma treatment at an industry conference. The data will be delivered as a late-breaking abstract, which will underline the safety and efficacy of MRx-4DP0004.
2022-04-01 03:29:43 - Proactive Investors
4D Pharma has a busy year ahead after a successful 12 months of clinical research
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has some significant milestones upcoming this year after a successful 12 months of developing assets that target the human microbiome, the bacterial ecosystem in the gut. The update was provided alongside prelims which showed the drug developer posted a £26.1mln operating loss in the year to 31 December 2021 after it spent £19.8mln on research and development.
2022-03-23 12:02:20 - Proactive Investors
4D Pharma PLC soars after meeting endpoint early
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) jumped 27% in London trading after the company hit its primary efficacy target in a phase I/II trail of one of its lead assets in kidney cancer. Chief Executive Officer Duncan Peyton described the progress as potentially “really meaningful” for patients and their families, in a conference call on Wednesday.
2022-03-23 09:43:03 - Benzinga
4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma
4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for renal cell carcinoma (RCC). The Part B of its signal finding study of MRx0518 &.
2022-03-23 03:56:18 - Proactive Investors
4D pharma sees early success as phase I/II cancer trial hits its efficacy target early
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it had hit its primary efficacy target in a phase I/II trial of one of its lead assets in kidney cancer. MRx0518 was used in combination with KEYTRUDA, the Merck blockbuster, which is a part of a class of drugs called immune checkpoint inhibitors (ICIs).
2022-02-22 02:56:43 - Proactive Investors
4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has received the green light for a first-in-human trial of its Parkinson's disease candidates in the US. This is after the Food & Drug Administration approved investigational new drug (IND) applications for MRx0005 and MRx0029.
2022-01-27 12:20:10 - Benzinga
4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy
As previously announced, Part A met the primary endpoint, and the safety profile of MRx-4DP0004 was comparable to placebo.
2022-01-27 02:39:40 - Proactive Investors
4D pharma hails 'highly encouraging' data from its early-stage asthma trial
4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has shared 'highly encouraging' follow-up data from its early-stage asthma trial using its lead live biotherapeutic asset. The first part of the phase I/II study revealed ‘multiple' signs that MRx-4DP0004 might help control the condition, supporting its move onto the second stage of the clinical evaluation process.